Pharmaceuticals, Biotechnology and Life Sciences
Oxford BioDynamics is one of six consortium partners to examine and address why immune-mediated inflammatory diseases (IMIDs) remit and relapse, with a particular focus on Rheumatoid Arthritis (RA).
Pfizer has decided to cancel listing of its stocks from the UK listing Authority List. The company said on Wednesday it also cancels trading on the main London Stock Exchange market.
Evgen Pharma has signed a services agreement with APTrans for developing its anti-stress drug SFX-01, currently in phase II clinical testing. APTrans is a Cheshire-based consortium of drug development companies.
Advanced Oncotherapy has dropped taking legal measures against Sinophi Healthcare Limited (Sinophi), as the companies have agreed to terminate the purchase from March and October 2015.
Kiadis Pharma has started its phase III trial with its major products for blood cancer hematopoietic stem cell transplantation (HSCT) ATIR101.
Novo Nordisk, the world’s top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit.
Advanced Oncotherapy said on Tuesday it will “appropriately” deal with a UK company Sinophi Healthcare, which invests in and manages hospitals in China, because it wanted to drop purchase orders made two years ago.
Avacta expects to license Affimer technology in 2017, and it says this year is very optimistic for its shareholders.
Onzima Ventures said on Tuestday it would buy another 51% of N4 Pharma Limited shares with 34609210 new ordinary shares of of 0.1p each in its capital. The acquisition should be completed by mid-April 2017.
Two UK-based biopharma companies, Mereo BioPharma and Diurnal have reshuffled their managerial lineups by swapping managers and welcoming new people.